← 프로그램 목록
세포·유전자 치료Phase 1Recruiting

Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells

National Cancer Institute (NCI)

비교

Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells(National Cancer Institute (NCI))은 BCMA 표적 세포·유전자 치료로, Myeloma-Multiple; Myeloma, Plasma-Cell 영역에서 개발·상용화 중입니다. 작용기전: targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor. Phase 1 안전성·PK 탐색 단계입니다. PFS: 36.6. 차별점: novel therapeutics.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 13일 (1일 전)PK/독성 2026년 7월 13일 (1일 전)

BCMA

Myeloma-Multiple; Myeloma, Plasma-Cell

Recruiting

Technology

구조모아 · StructureMoa에서 구조 검색

bispecific antibodies in relapsed or refractory multiple myeloma

in

lentiviral constructs, and durable clearance of myeloma cells after multiple rechallenges

humanized bispecific antibody approved for patients with relapsed/refractory multiple myeloma (RRMM)

novel therapeutics

Mechanism of Action

targets for bsAbs on multiple myeloma cells are B cell maturation antigen (BCMA), G-protein-coupled receptor family C group 5 member D (GPRC5D), and Fc receptor

cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as significant infecti

apoptosis through microtubule inhibition, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagoc

BCMA) is a high

Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 73건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 1 · Phase 2 · Phase 1, Phase 2
  • Status: Recruiting · Active, not recruiting · Completed
  • 주요 endpoint: Occurrence of Treatment Emergent Adverse Events (TEAEs) · Severity of TEAEs · Occurrence of Adverse Events of Special Interest (AESI) · Severity of AESIs · Occurrence of Serious Adverse Events (SAEs)
  • PFS: 36.6
  • 핵심: This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in comb…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells은 어떤 치료제인가요?
Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells(National Cancer Institute (NCI))은 BCMA 표적 세포·유전자 치료로, Myeloma-Multiple; Myeloma, Plasma-Cell 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells의 임상 단계는?
Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells의 현재 단계는 Phase 1입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.